David Shook
Nkarta, Inc. · St. Jude Children's Research Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Shook as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:41 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05020678 · NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersNkarta, Inc. · active not recruiting · Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma · study director
- Ph1NCT04623944 · NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSNkarta, Inc. · active not recruiting · Relapsed/Refractory AML, AML, Adult, MDS · study director
- Ph1NCT00995137 · Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital · completed · Lymphoblastic Leukemia, Acute · principal investigator
- Ph1NCT00640796 · Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsSt. Jude Children's Research Hospital · completed · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cell Therapy of Refractory LeukemiaR01CA113482 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI DARIO CAMPANA · fiscal years 2006 to 2010Named on NCT00995137, NCT00640796
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:41 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease.Biol Blood Marrow Transplant · 2013119 citationsRCR 4.2
- Real-time three-dimensional transesophageal echocardiography in valve disease: comparison with surgical findings and evaluation of prosthetic valves.J Am Soc Echocardiogr · 2008115 citationsRCR 3.9
- Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion.Transpl Infect Dis · 201853 citationsRCR 2.0
- Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.Biol Blood Marrow Transplant · 201743 citationsRCR 1.4
- Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability.Pediatr Blood Cancer · 201538 citationsRCR 1.1
- Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.Biol Blood Marrow Transplant · 201412 citationsRCR 0.4
- Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study.PLoS One · 201512 citationsRCR 0.8